AbbVie cut workers, cut research by 29%, gave the CEO a 75% raise, spent billions on advertising, and charged patients prices justified by innovation the company's own financial decisions were actively defunding. When those are the facts on the table, the innovation argument isn't a business case. It's a cover story — and the filings that prove it are public record.